Compare RYAM & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | MRVI |
|---|---|---|
| Founded | 1926 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.1M | 449.6M |
| IPO Year | N/A | 2020 |
| Metric | RYAM | MRVI |
|---|---|---|
| Price | $5.84 | $3.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $6.00 | $4.57 |
| AVG Volume (30 Days) | 544.0K | ★ 1.2M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,471,356,000.00 | $192,435,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.99 | $9.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.35 | $1.67 |
| 52 Week High | $8.56 | $6.21 |
| Indicator | RYAM | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 43.08 |
| Support Level | $5.59 | $3.44 |
| Resistance Level | $5.92 | $3.59 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 27.93 | 7.14 |
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.